Read this industry report to learn key insights on biosimilars in 2024, including market trends, policy changes, payer coverage, and new drug developments like Eylea® biosimilars.
In the 2024 Biosimilars Report: insights on a pivotal year of evolution and expansion, industry leaders weighed in on the economic, competitive, legislative and societal developments that were likely to have the biggest impact in 2024. The report included the industry data on utilization, government pricing, reform and payer coverage. Lastly, the report included insights from retina specialists on new drug releases, like biosimilars for Eylea®, a highly successful drug used to treat retinal diseases.
Sponsored by
